Celcuity (NASDAQ:CELC) Shares Gap Up - Still a Buy?

Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $13.63, but opened at $14.18. Celcuity shares last traded at $13.94, with a volume of 25,894 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CELC shares. Needham & Company LLC restated a "buy" rating and set a $29.00 target price on shares of Celcuity in a research report on Monday, June 30th. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Celcuity in a research report on Monday, May 19th. Finally, Stifel Nicolaus started coverage on Celcuity in a research report on Tuesday, July 1st. They set a "buy" rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Celcuity has a consensus rating of "Buy" and an average price target of $28.40.

Celcuity Trading Down 0.8%

The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. The firm has a fifty day simple moving average of $11.97 and a 200-day simple moving average of $11.32. The firm has a market cap of $520.71 million, a P/E ratio of -4.54 and a beta of 0.45.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. On average, equities research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CELC. Rhumbline Advisers increased its position in shares of Celcuity by 8.9% during the first quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock valued at $427,000 after acquiring an additional 3,439 shares during the last quarter. Baker BROS. Advisors LP increased its position in shares of Celcuity by 59.0% during the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock valued at $43,046,000 after acquiring an additional 1,579,182 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Celcuity during the first quarter valued at approximately $215,000. Tema Etfs LLC purchased a new stake in shares of Celcuity during the first quarter valued at approximately $158,000. Finally, Trexquant Investment LP increased its position in shares of Celcuity by 131.3% during the first quarter. Trexquant Investment LP now owns 26,920 shares of the company's stock valued at $272,000 after acquiring an additional 15,280 shares during the last quarter. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.